Trial Profile
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ZEAL; ZEST
- Sponsors Spectrum Pharmaceuticals
- 06 Apr 2022 This trial has been completed in Netherland (End Date: 23 Oct 2014), according to European Clinical Trials Database record.
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 16 Oct 2017 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.